Radiation plus immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that hasn't been treated before and can't be surgically removed.
- Your cancer is stage II (unresectable) or stage III, and you're eligible for standard chemo and radiation.
- You have a tumor sample tested for PD-L1 levels.
- You have adequate organ function (kidneys, liver, blood counts) and an ECOG performance status of 0-2.
- You have no known EGFR or ALK mutations (gene changes that respond to different treatments).
- You haven't had prior immunotherapy with PD-1, PD-L1, or LAG-3 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial compares two treatment approaches before surgery for non-small cell lung cancer (NSCLC): radiation plus immunotherapy versus chemotherapy plus immunotherapy. The goal is to see which combination works better to shrink the tumor before it is removed.
This trial is testing a combination of treatments (an immunotherapy drug called cemiplimab plus chemotherapy) for people with advanced lung cancer that has not been treated yet and shows a high PD-L1 level. The study also looks at a specific blood marker to see if it predicts how the cancer responds, aiming to avoid rapid growth (hyperprogression).
This trial tests whether adding an immunotherapy drug called cemiplimab to chemotherapy before a shorter course of radiation helps older or less fit patients with stage III lung cancer. It aims to improve treatment results while being more manageable for patients who might not tolerate standard therapies.
This study tests a new immunotherapy drug (cemiplimab) combined with chemotherapy for advanced squamous lung cancer. The treatment is chosen based on a blood test that measures a natural body enzyme, which may help predict how well the chemotherapy works.
Hear when a new Locally Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.